Update on newer antipsychotic drugs

Journal of Psychosocial Nursing and Mental Health Services

Volumn 49, Issue 4, 2011, Pages 13-15

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955418291     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20110311-99     Document Type: Review

References (8)

1. Albers, L.J., Musenga, A., & Raggi, M.A. (2008). Iloperidone: A new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opinion on Investigational Drugs, 17, 61-75.
2. Citrome, L. (2009). Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. International Journal of Clinical Practice, 63, 1762-1784.
3. Citrome, L. (2011). Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice, 65, 189-210.
4. Drugs for psychotic disorders. (2010). Treatment Guidelines from the Medical Letter, 8(96), 61-64.
5. Howland, R.H. (2007). Paliperidone extended-release tablets: A new atypical antipsychotic. Journal of Psychosocial Nursing and Mental Health Services, 45(5), 15-18.
6. Howland, R.H. (2011). Vilazodone: Another novel atypical antidepressant drug. Journal of Psychosocial Nursing and Mental Health Services, 49(3), 19-22.
7. Leonard, B.E. (1978). Mianserin, an antidepressant with a unique neuropharmacological profile. Acta Psychiatrica Belgica, 78, 770-780.
8. Nickolson, V.J., Wieringa, J.H., & van Delft, A.M. (1982). Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmiedeberg's Archives of Pharmacology, 319, 48-55.